For questions regarding claiming CME Credit, please refer to our FAQ section.

 
           
Post-AHA 2014 Webcast

Program Overview:

Questions surrounding dual antiplatelet therapy (DAPT) may be answered with trials presented at AHA 2014. Discontinuing DAPT at 6 months with second-generation DES was examined in the ISAR-SAFE and Italic trials. Continuing DAPT up to 30 months wass examined with the anticipated DAPT Study which randomized 9,000 patients to DAPT or aspirin and placebo after 12 months. Following the data presentation, a panel discussion with audience questions will put the recent findings from ISAR-SAFE, Italic, and DAPT studies into context of existing DAPT practices.


Click Here to access this CME Program   
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour    


Post-TCT Webcast: Refining TAVR Therapies

Program Overview:

Long-term valve durability, stroke complications, and costs remain important considerations when treating patients with transcatheter aortic valve replacement (TAVR) for aortic stenosis. Currently, Medicare reimbursement in the United States is limited to transfemoral TAVR based on cost-effectiveness data. Also, the risk of stroke persists, with the STS/ACC TVT Registry reporting a 30-day stroke rate of 2.8% in general practice. In this live webcast, four internationally renowned experts will discuss important trial data presented at TCT 2014, which will further illuminate the challenges of stroke, cost, and durability associated with TAVR.

Click Here to access this CME Program   
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour    

Post-TCT 2014 Webcast: New Coronary Devices and Approaches – ABSORB, DKCRUSH, and RIBS-IV

Program Overview:

Best practices in treating bifurcations and drug-eluting stent restenosis are constantly evolving for PCI. Recent trials presented at TCT 2014 illuminate these changes as technology evolves. DES restenosis is less common than with BMS but still occurs at estimates of 3%-10% for second-generation DES. Currently, limited data exist to illustrate differences in outcomes between treatment with angioplasty using a plain balloon or paclitaxel-eluting balloon or implanting a second DES. The RIBS-IV study compared outcomes of drug-eluting stents with those of paclitaxel-eluting balloons for treating DES restenosis.

Provisional stenting is the recommended practice for treating bifurcation lesions at present. The role of imaging and physiologic measurement practices have yet to be determined for side branch lesion assessment. The DKCRUSH trial examines the role of FFR for side branch assessment.

Bioresorbable vascular scaffolds are called the “next revolution” in stenting for PCI. However, long-term outcomes data and comparisons to current stents have been lacking. ABSORB II reports the 1-year outcomes for the Absorb bioresorbable scaffold (Abbott Vascular) compared with those of an everolimus-eluting stent.  


Click Here to access this CME Program    
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour   

Late Breaking Trials from ACC, CIT and EuroPCR:   Bivalirudin vs. Heparin in STEMI

Program Overview:

Trial reports from the Spring 2014 meetings have muddied the controversies regarding bivalirudin versus heparin for PCI. Both bivalirudin and heparin are Level I recommendations as adjunct anticoagulants during PCI for STEMI. Bivalirudin is recommended over heparin when elevated bleeding risk is present because of the mortality benefit from reduced bleeding events including those that occur periprocedurally. However, bivalirudin’s high cost and increased risk of stent thrombosis remain drawbacks.

This webcast will revisit the collective issue of bivalirudin vs heparin for STEMI PCI.  

Click Here to access this CME Program   
Release Date:
October 16th, 2014

Expiration Date:
April 16th, 2015 

Estimated Time:
1 hour    


 
DAPT CME Program Overview:

This webcast examines common clinical dilemmas with dual antiplatelet therapy including noncardiac surgeries, DAPT plus anticoagulants for atrial fibrillation patients post-PCI, and managing bleeding complications with DAPT or triple therapy. Clinical tools and recent clinical trial data are discussed to help physicians with decision-making around DAPT.

Click Here to access this CME Program   
Release Date:
October 16th, 2014

Expiration Date:
April 16th, 2015 

Estimated Time:
1 hour